Request an Appointment

Cancer Answer Line:

M-F 8 a.m. - 4:30 p.m. ET

Expand Content

Cancer Clinical Trials Results

BYLR 111414-770Scalp Cooling Alopecia Prevention Trial (SCALP)Main Campus  Breast
CASE 1611212-1352Association between Mammostrat score and pathologic response to neoadjuvant chemotherapy in Estrogen Receptor positive (ER+) early stage breast cancerMain Campus  Breast
CASE 411313-753A Pilot Study for Evaluating the Neural Substrates of Cognitive impairments and movement-related fatigue in women undergoing adjuvant chemotherapy (CARES)Main Campus  Breast
CLDX 111414-506A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)Main Campus  Breast
ECOG 2108CC13-074A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast CancerFlorida WestonStage 4Phase 3Breast
NLG 111314-521A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Docetaxel in Combination with 1-methyl-D-tryptophan (indoximod) in Metastatic Breast CancerFlorida Weston, Main Campus Phase 2Breast
NSABP B43CC715A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by LumpectomyBeachwood, Fairview, Hillcrest, Independence, Main Campus, North Coast Cancer, Strongsville, Wooster Phase 3Breast
NSABP B4713-1408A Randomized Phase III Trial of Adjuvant Therapy comparing chemotherapy alone (Six Cycles of Docetaxel plus cyclophosphamide of four cycles of doxorubicin plus cyclophosphamide followed by weekly Paclitaxel) to chemotherapy plus Trastuzumab in Women with Node-Positive of High-Risk Node Negative HER2-Low invasive Breast Cancer.Beachwood, Fairview, Hillcrest, Independence, Main Campus, North Coast Cancer, Strongsville, Wooster Phase 3Breast
NSABP B5114-434A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant ChemotherapyBeachwood, Fairview, Hillcrest, Independence, Main Campus, North Coast Cancer, Strongsville, Wooster Phase 3Breast
ROCH 1113061310CA Randomized, Multicenter, Open-Label Phase III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine Versus Trastuzumab As Adjuvant Therapy For Patients With Her2-Positive Primary Breast Cancer Who Have Residual Tumor Present Pathologically In The Breast Or Axillary Lymph Nodes Following Preoperative TherapyFairview, Hillcrest, Main Campus Phase 3Breast
RTOG 111913-551Phase II Randomized study of whole brain radiotherapy in combination with concurrent lapatinib in patients with brain metastasis from HER2-Positive Breast cancer. A collaborative study of RTOG and KROG.Beachwood, Fairview, Hillcrest, Independence, North Coast Cancer, Parma, Strongsville, Wooster Phase 2Brain, Breast
SWOG 1007CC00111A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast CancerBeachwood, Fairview, Hillcrest, Independence, Main Campus, North Coast Cancer, Parma, Strongsville, Wooster Phase 3Breast
SWOG 120713-640Phase III Randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk hormone receptor-positive and HER2/NEU negative breast cancer. E^3 Breast Cancer Study- Evaluating Everolimus with Endocrine TherapyBeachwood, Fairview, Hillcrest, Independence, Main Campus, North Coast Cancer, Strongsville, Wooster Phase 3Breast
SWOG 122214-991Fulvestrant Alone Versus Fulvestrant and Everolimus VersusFulvestrant, Everolimus and Anastrozole: A Phase III Randomized Placebo-Controlled Trial in Postmenopausal Patients with Hormone-Receptor PositiveStage IV Breast CancerFlorida Weston, Main Campus Phase 3Breast
UPCI 111111-1226The ACTS Intervention to Reduce Breast Cancer Treatment DisparityMain Campus  Breast

Cancer Answers & Appointments

Speak with a cancer nurse specialist for appointment assistance and for answers to your questions about cancer locally at 216.444.7923 or toll-free 1.866.223.8100.

Monday through Friday from 8 a.m. – 4:30 p.m. (ET).


Resources for medical professionals

  • Outpatient appointment referrals: 216.444.7923 or 866.223.8100
  • Inpatient hospital transfers: 800.553.5056
  • Referring Physician Concierge: 216.444.6196 or 216.312.4910.

Clinical Trials

Search available cancer clinical trials by disease, hospital, phase or number.

This information is provided by Cleveland Clinic and is not intended to replace the medical advice of your doctor or health care provider. Please consult your health care provider for advice about a specific medical condition.

© Copyright 2014 Cleveland Clinic. All rights reserved.